Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF
Top Page
Cardiff Oncology
(NASDAQ:CRDF)
45Neutral
Positive Factors
Clinical Trials
Onvansertib 30mg combined with standard-of-care demonstrated a 64% objective response rate, showing highly promising results in the CRDF-004 trial.
Financial Performance
The probability of approval for onvansertib has been raised to 40%, and the 12-month price target for Cardiff Oncology shares has been increased to $17.
Market Potential
The KRAS+ colorectal cancer market is underserved, and successful results with onvansertib could drive a paradigm shift in treatment and make Cardiff Oncology an attractive acquisition target.
Negative Factors
Approval Challenges
Risks also include delays in advancing onvansertib into pivotal clinical studies and failure to obtain onvansertib approval.
Clinical Risks
Risks include negative or poorer-than-anticipated clinical results for onvansertib in the ongoing CRDF-004 trial.
Cardiff Oncology (CRDF) vs. S&P 500 (SPY)
Market Cap
$228.84M
Dividend YieldN/A
Average Volume (3M)1.13M
Price to Earnings (P/E)―
Beta (1Y)1.16
Revenue Growth40.16%
EPS Growth-2.76%
CountryUS
Employees31
SectorHealthcare
Sector Strength64
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.95
Shares Outstanding66,524,290
10 Day Avg. Volume1,037,278
30 Day Avg. Volume1,127,494
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)365.25
Price to Cash Flow (P/CF)-6.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$15.67Price Target Upside355.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Cardiff Oncology Business Overview & Revenue Model
Company DescriptionCardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
How the Company Makes MoneyCardiff Oncology generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company makes money by advancing its clinical trials and securing partnerships or licensing agreements with larger pharmaceutical companies who are interested in co-developing or acquiring rights to its therapies. Cardiff Oncology may also receive milestone payments and royalties from these partnerships, which can significantly contribute to its earnings. Additionally, the company might engage in fundraising through public offerings or private placements to support its research and development efforts. However, as a clinical-stage company, Cardiff Oncology's revenue sources are largely dependent on the progress and success of its drug development programs and collaborations.
Cardiff Oncology Financial Statement Overview
Summary
Cardiff Oncology faces significant financial hurdles, primarily driven by an absence of revenue and persistent losses. While the balance sheet is stable with strong equity, the lack of profitability and negative cash flows pose major challenges. The company needs to improve its revenue generation and operational efficiency to advance towards financial stability.Income Statement
Cardiff Oncology's income statement reveals significant financial challenges. The company has consistently negative EBIT and net income, indicating ongoing operational losses. Revenue growth is stagnant, with a decrease in total revenue from $488,000 in 2023 to $0 in 2024. The lack of revenue in 2024 highlights the company's struggle in generating sales, a critical factor for long-term sustainability.15
Very Negative
Balance Sheet
The balance sheet shows a relatively stable financial position with strong stockholders' equity compared to total liabilities, resulting in a low debt-to-equity ratio. However, the company has a high level of cash relative to debt, which provides a cushion but also indicates inefficient capital utilization. The equity ratio remains robust, suggesting a solid capital structure.45
Neutral
Cash Flow
Cardiff Oncology's cash flow statement reflects ongoing challenges in cash generation. The company has negative free cash flow and operating cash flow, indicating cash outflows from operations. Despite a positive financing cash flow in 2024, the reliance on external financing to cover operational shortfalls highlights sustainability concerns.30
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 683.00K | 488.00K | 386.00K | 359.00K | 365.99K | Gross Profit |
| 683.00K | 488.00K | 186.00K | -141.00K | -10.87M | EBIT |
| -48.65M | -45.41M | -39.90M | -28.86M | -19.09M | EBITDA |
| -48.65M | -45.01M | -39.67M | -28.40M | -18.84M | Net Income Common Stockholders |
| -45.45M | -41.44M | -37.51M | -27.74M | -19.28M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 91.75M | 74.82M | 105.27M | 140.82M | 130.98M | Total Assets |
| 97.19M | 81.64M | 116.19M | 149.54M | 134.73M | Total Debt |
| 1.52M | 2.15M | 2.71M | 3.12M | 869.50K | Net Debt |
| -49.95M | -19.51M | -13.63M | -8.82M | -130.11M | Total Liabilities |
| 14.24M | 11.90M | 9.85M | 9.13M | 6.57M | Stockholders Equity |
| 82.95M | 69.74M | 106.34M | 140.42M | 128.16M |
| Cash Flow | Free Cash Flow | |||
| -37.77M | -31.47M | -34.71M | -23.25M | -16.53M | Operating Cash Flow |
| -37.69M | -30.89M | -33.82M | -23.04M | -16.31M | Investing Cash Flow |
| 13.73M | 36.20M | 38.15M | -131.45M | -211.88K | Financing Cash Flow |
| 53.78M | 0.00 | 75.00K | 35.45M | 137.31M |
Cardiff Oncology Technical Analysis
Negative
3.44
Price Trends
3.98
Negative
3.71
Negative
3.09
Positive
Market Momentum
-0.13
Positive
39.16
Neutral
13.11
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRDF, the sentiment is Negative. The current price of 3.44 is below the 20-day moving average (MA) of 3.85, below the 50-day MA of 3.98, and above the 200-day MA of 3.09, indicating a neutral trend. The MACD of -0.13 indicates Positive momentum. The RSI at 39.16 is Neutral, neither overbought nor oversold. The STOCH value of 13.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRDF.
Cardiff Oncology Risk Analysis
Cardiff Oncology disclosed 53 risk factors in its most recent earnings report. Cardiff Oncology reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cardiff Oncology Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $10.55B | 20.88 | 23.13% | ― | 18.49% | 176.71% | |
75 Outperform | $134.36B | 282.07 | 2.28% | 2.82% | 6.16% | -91.54% | |
58 Neutral | $6.41B | 292.19 | 12.21% | ― | 40.80% | 100.62% | |
52 Neutral | $5.95B | ― | -31.26% | ― | 104.04% | 87.80% | |
49 Neutral | $6.86B | 0.72 | -52.93% | 2.49% | 20.83% | 1.11% | |
45 Neutral | $228.84M | ― | -59.51% | ― | 40.16% | -2.76% | |
40 Underperform | $47.13M | ― | 41.08% | ― | -0.55% | 49.85% |
* Healthcare Sector Average
Performance Comparison
CRDF
Cardiff Oncology
3.44
-1.90
-35.58%
EXEL
Exelixis
36.84
13.11
55.25%
GILD
Gilead Sciences
111.16
40.56
57.45%
KPTI
Karyopharm Therapeutics
4.35
-18.30
-80.79%
TGTX
TG Therapeutics
40.20
24.99
164.30%
BPMC
Blueprint Medicines
89.73
-5.13
-5.41%
Cardiff Oncology Earnings Call Summary
Earnings Call Date: Feb 27, 2025 | % Change Since: -15.27% | Next Earnings Date: May 1, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong initial clinical data, successful capital raising efforts, and a solid financial position. However, some dependency on future FDA meetings and the early stage of PFS data might pose challenges. Overall, the sentiment is optimistic with clear progress, yet some uncertainties remain.Highlights
Encouraging Initial Data from CRDF-004 Trial
The trial showed a 64% ORR for patients on the 30 mg dose of onvansertib, compared to a 33% ORR in the control arm, indicating a strong efficacy signal.
Successful Capital Raise
Cardiff Oncology successfully completed a $40 million capital raise, enhancing financial stability and resources for future developments.
Advancement in Intellectual Property
A new patent was issued covering the use of onvansertib with bevacizumab for KRAS-mutated mCRC, extending intellectual property protection until at least 2043.
Strong Financial Position
Cash and short-term investments totaled $91.7 million, providing a financial runway into Q1 2027.
Positive Preclinical Results in Breast Cancer
Onvansertib showed promising results in preclinical studies, demonstrating synergistic activity with paclitaxel and ENHERTU in drug-resistant HR-positive breast cancer models.
Lowlights
Pending FDA Discussions
While progress has been made, key decisions regarding dose selection and trial design depend on future FDA meetings, which could impact timelines.
Limited Data on Progression-Free Survival (PFS)
It is too early to report PFS data from the CRDF-004 trial, leaving uncertainty about long-term efficacy and potential for full approval.
Company Guidance
During the Cardiff Oncology Fourth Quarter 2024 Financial Results and Business Update Conference Call, guidance was provided on several key metrics and future plans for the company. The company highlighted an initial data set from the CRDF-004 trial, which showed a 64% overall response rate (ORR) for patients on the 30 mg dose of onvansertib, compared to 33% in the control arm. The trial focuses on first-line RAS-mutated metastatic colorectal cancer (mCRC), and aims to complete enrollment of 90 evaluable patients in early 2025. The company plans to release additional clinical data in the first half of 2025. Financially, Cardiff Oncology reported $91.7 million in cash and short-term investments as of December 31, 2024, following a $40 million capital raise. The company projects that these resources will support operations into the first quarter of 2027, with a quarterly cash burn of $10.3 million in Q4 2024. Additionally, Cardiff Oncology strengthened its intellectual property portfolio with a new patent for onvansertib, expected to expire no earlier than 2043.Cardiff Oncology Corporate Events
Business Operations and Strategy
Cardiff Oncology Reports Promising Phase 2 Trial Results
Positive
Dec 10, 2024
Cardiff Oncology has reported promising initial results from its Phase 2 trial (CRDF-004) testing onvansertib with standard care in first-line RAS-mutated metastatic colorectal cancer. The data suggests enhanced efficacy with onvansertib, showing higher overall response rates compared to standard treatments alone. This development could represent a significant breakthrough for investors watching the oncology sector, though risks and uncertainties remain as the trials progress.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.